JP6829691B2 - 創傷治癒に使用するための植物抽出物及び化合物 - Google Patents
創傷治癒に使用するための植物抽出物及び化合物 Download PDFInfo
- Publication number
- JP6829691B2 JP6829691B2 JP2017548347A JP2017548347A JP6829691B2 JP 6829691 B2 JP6829691 B2 JP 6829691B2 JP 2017548347 A JP2017548347 A JP 2017548347A JP 2017548347 A JP2017548347 A JP 2017548347A JP 6829691 B2 JP6829691 B2 JP 6829691B2
- Authority
- JP
- Japan
- Prior art keywords
- tancinone
- salvia
- cyp11b1
- medicament
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 63
- 239000000284 extract Substances 0.000 title description 67
- 230000029663 wound healing Effects 0.000 title description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 73
- 206010052428 Wound Diseases 0.000 claims description 71
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 claims description 49
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 claims description 49
- 235000017276 Salvia Nutrition 0.000 claims description 48
- 230000001684 chronic effect Effects 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 23
- 239000000419 plant extract Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 208000014311 Cushing syndrome Diseases 0.000 claims description 11
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 11
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 6
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 241001072909 Salvia Species 0.000 claims 1
- 240000007164 Salvia officinalis Species 0.000 description 49
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 21
- 229960000890 hydrocortisone Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 241000612118 Samolus valerandi Species 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 241000887044 Myripnois Species 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 4
- 101100219201 Homo sapiens CYP11B1 gene Proteins 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 244000132619 red sage Species 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010011985 Decubitus ulcer Diseases 0.000 description 3
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 240000008125 Salvia polystachya Species 0.000 description 3
- 235000006108 Salvia polystachya Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical group O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 235000001499 Salvia glutinosa Nutrition 0.000 description 2
- 240000006476 Salvia glutinosa Species 0.000 description 2
- 235000002299 Salvia leucophylla Nutrition 0.000 description 2
- 241000862239 Salvia leucophylla Species 0.000 description 2
- 235000002912 Salvia officinalis Nutrition 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 240000001735 chia Species 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002278 reconstructive surgery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000001590 sorbitan monolaureate Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- -1 4,5-dimethylthiazole-2-yl Chemical group 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 241001268392 Dalla Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000005410 Mexican sage Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 235000002302 Salvia apiana Nutrition 0.000 description 1
- 235000001496 Salvia argentea Nutrition 0.000 description 1
- 241000227765 Salvia argentea Species 0.000 description 1
- 244000159860 Salvia arizonica Species 0.000 description 1
- 235000006103 Salvia arizonica Nutrition 0.000 description 1
- 235000002300 Salvia azurea Nutrition 0.000 description 1
- 244000126818 Salvia azurea Species 0.000 description 1
- 244000260602 Salvia carnosa Species 0.000 description 1
- 235000006863 Salvia carnosa Nutrition 0.000 description 1
- 235000006274 Salvia clevelandii Nutrition 0.000 description 1
- 244000113863 Salvia clevelandii Species 0.000 description 1
- 235000012223 Salvia coccinea Nutrition 0.000 description 1
- 244000178134 Salvia coccinea Species 0.000 description 1
- 235000016274 Salvia dorrii Nutrition 0.000 description 1
- 241001226049 Salvia dorrii Species 0.000 description 1
- 235000006269 Salvia farinacea Nutrition 0.000 description 1
- 244000113842 Salvia farinacea Species 0.000 description 1
- 241000355338 Salvia forreri Species 0.000 description 1
- 235000010807 Salvia fulgens Nutrition 0.000 description 1
- 241000862354 Salvia fulgens Species 0.000 description 1
- 244000048669 Salvia funerea Species 0.000 description 1
- 235000015356 Salvia funerea Nutrition 0.000 description 1
- 235000006290 Salvia greggii Nutrition 0.000 description 1
- 241000122625 Salvia greggii Species 0.000 description 1
- 235000004062 Salvia guaranitica Nutrition 0.000 description 1
- 241001184577 Salvia guaranitica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 235000000084 Salvia leucantha Nutrition 0.000 description 1
- 241000261355 Salvia leucantha Species 0.000 description 1
- 241001643689 Salvia longistyla Species 0.000 description 1
- 235000006141 Salvia lyrata Nutrition 0.000 description 1
- 241000122632 Salvia lyrata Species 0.000 description 1
- 235000002887 Salvia mexicana Nutrition 0.000 description 1
- 244000120680 Salvia mexicana Species 0.000 description 1
- 235000000524 Salvia patens Nutrition 0.000 description 1
- 241000862254 Salvia patens Species 0.000 description 1
- 235000001503 Salvia pratensis Nutrition 0.000 description 1
- 244000251853 Salvia pratensis Species 0.000 description 1
- 235000006104 Salvia roemeriana Nutrition 0.000 description 1
- 241000122595 Salvia roemeriana Species 0.000 description 1
- 235000002911 Salvia sclarea Nutrition 0.000 description 1
- 244000182022 Salvia sclarea Species 0.000 description 1
- 235000006107 Salvia spathacea Nutrition 0.000 description 1
- 241000122590 Salvia spathacea Species 0.000 description 1
- 235000017668 Salvia splendens Nutrition 0.000 description 1
- 240000001438 Salvia splendens Species 0.000 description 1
- 235000001502 Salvia verticillata Nutrition 0.000 description 1
- 241000227806 Salvia verticillata Species 0.000 description 1
- 235000001486 Salvia viridis Nutrition 0.000 description 1
- 244000258070 Salvia viridis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000001691 salvia sclarea Substances 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6955—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a plaster, a bandage, a dressing or a patch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1421479.5A GB201421479D0 (en) | 2014-12-03 | 2014-12-03 | A plant extract and compounds for use in wound healing |
| GB1421479.5 | 2014-12-03 | ||
| PCT/GB2015/000312 WO2016087810A1 (en) | 2014-12-03 | 2015-11-30 | A plant extract and compounds for use in wound healing |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537163A JP2017537163A (ja) | 2017-12-14 |
| JP2017537163A5 JP2017537163A5 (enExample) | 2019-01-17 |
| JP6829691B2 true JP6829691B2 (ja) | 2021-02-10 |
Family
ID=52349874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548347A Expired - Fee Related JP6829691B2 (ja) | 2014-12-03 | 2015-11-30 | 創傷治癒に使用するための植物抽出物及び化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180228858A1 (enExample) |
| EP (1) | EP3226879A1 (enExample) |
| JP (1) | JP6829691B2 (enExample) |
| CN (1) | CN107135645A (enExample) |
| GB (2) | GB201421479D0 (enExample) |
| WO (1) | WO2016087810A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102687221B1 (ko) * | 2016-12-05 | 2024-07-22 | 주식회사 엘지생활건강 | 디하이드로탄시논 ⅰ을 포함하는 구강질환 예방 또는 치료용 조성물 |
| CN110251716B (zh) * | 2019-04-22 | 2020-12-18 | 张贤慧 | 一种伤口护理用凝胶敷料及其制备方法 |
| TWI750705B (zh) * | 2020-06-19 | 2021-12-21 | 慈濟學校財團法人慈濟大學 | 預防及/或治療壓力誘發疾病之方法 |
| US20210393585A1 (en) * | 2020-06-19 | 2021-12-23 | Tzu Chi University | Method for preventing and/or treating a stress-induced disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59163319A (ja) * | 1983-03-07 | 1984-09-14 | Sawai Seiyaku Kk | 抗真菌剤 |
| JPH0830077B2 (ja) * | 1987-04-24 | 1996-03-27 | 晟 八木 | 虚血性疾患治療剤 |
| DE4303823C2 (de) * | 1993-02-10 | 1997-08-07 | Isernhagen Heilmittelbetr Gmbh | Verwendung eines Extraktes aus Blüten von Salvia officinalis bei der Bekämpfung von Durchblutungsstörungen |
| KR100861186B1 (ko) * | 2001-03-26 | 2008-09-30 | 주식회사 엘지생활건강 | 크립토탄시논을 함유하는 여드름 예방 및 치료용 화장료 |
| CN102579460B (zh) * | 2003-12-30 | 2015-04-29 | 麦仁斯有限公司 | 用增强代谢活性的丹参衍生物治疗肥胖和代谢综合症 |
| CA2595564C (en) * | 2005-02-16 | 2015-03-31 | Md Bioalpha Co., Ltd. | Use of .beta.-lapachone and related naphthoquinones in the treatment of amp-activated protein kinase (ampk) mediated disorders |
| KR100725839B1 (ko) * | 2005-10-06 | 2007-12-11 | 일성신약주식회사 | 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| GB2453807A (en) * | 2007-10-15 | 2009-04-22 | Botan Century | Purified tanshinone extracts from Salvia spp and their antibacterial effects |
| JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ｐｐａｒ活性化剤 |
| CN101642486B (zh) * | 2009-08-28 | 2011-09-21 | 湖南省中医药研究院 | 一种促进创伤愈合的中药组合物及其制备方法 |
| CN102579650B (zh) * | 2011-03-10 | 2014-02-26 | 成都中医药大学 | 一种预防或/和治疗压疮的药物组合物及其制备方法和用途 |
| CN102727581B (zh) * | 2011-04-11 | 2016-02-10 | 苏州瑞美科生物技术有限公司 | 一种对伤口具有修复作用的药物组合物 |
| CN103356844B (zh) * | 2012-03-28 | 2015-12-16 | 苏州瑞美科生物技术有限公司 | 一种低聚壳聚糖复方制剂及其在制备治疗皮肤疾病的药物中应用 |
| CN102824599B (zh) * | 2012-08-07 | 2013-12-25 | 孟庆德 | 一种治疗糖尿病引起的各种皮肤溃烂的中药酊剂 |
| CN102988370A (zh) * | 2012-11-23 | 2013-03-27 | 广东省中医院 | 丹参酮i在制备治疗银屑病药物中的应用 |
| CN103830175A (zh) * | 2012-11-26 | 2014-06-04 | 青岛百草汇中草药研究所 | 含有丹参酮的乳剂及其制备方法 |
| CN103040956A (zh) * | 2013-01-18 | 2013-04-17 | 江其生 | 一种能预防和治疗皮肤放射损伤的中药组合物 |
| CN103230493B (zh) * | 2013-04-15 | 2015-04-22 | 杨少辉 | 一种治疗创口不愈的中药组合物 |
| CN103705616A (zh) * | 2014-01-02 | 2014-04-09 | 魏春战 | 一种祛腐生肌膏的配方 |
-
2014
- 2014-12-03 GB GBGB1421479.5A patent/GB201421479D0/en not_active Ceased
-
2015
- 2015-11-30 CN CN201580073703.XA patent/CN107135645A/zh active Pending
- 2015-11-30 JP JP2017548347A patent/JP6829691B2/ja not_active Expired - Fee Related
- 2015-11-30 WO PCT/GB2015/000312 patent/WO2016087810A1/en not_active Ceased
- 2015-11-30 EP EP15807964.0A patent/EP3226879A1/en not_active Withdrawn
- 2015-11-30 US US15/533,009 patent/US20180228858A1/en not_active Abandoned
- 2015-12-01 GB GB1521166.7A patent/GB2538580B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20180228858A1 (en) | 2018-08-16 |
| GB201521166D0 (en) | 2016-01-13 |
| CN107135645A (zh) | 2017-09-05 |
| GB201421479D0 (en) | 2015-01-14 |
| GB2538580A (en) | 2016-11-23 |
| GB2538580B (en) | 2019-07-24 |
| WO2016087810A1 (en) | 2016-06-09 |
| JP2017537163A (ja) | 2017-12-14 |
| EP3226879A1 (en) | 2017-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU778261B2 (en) | Extracts of feverfew (tanacetum parthenium) against inflammatory disorders | |
| JP6829691B2 (ja) | 創傷治癒に使用するための植物抽出物及び化合物 | |
| KR102302304B1 (ko) | 2-푸코실락토오스를 포함하는 자가포식 활성 유도용 조성물 | |
| KR101100678B1 (ko) | 식물 추출물을 함유하는 화장료 조성물 | |
| FR3075642A1 (fr) | Extrait de fleurs de kapokier et compositions cosmetiques, pharmaceutiques ou dermatologiques le comprenant | |
| US20190008757A1 (en) | Dermatological or cosmetic compositions containing a polyphenol?enriched extract of vitex negundo | |
| JP7728774B2 (ja) | ヘチマ根抽出物を含む組成物 | |
| KR20100103479A (ko) | 오르키드 추출물을 포함하는 화장품 또는 피부학적 조성물 및 상기 조성물을 사용한 화장 케어 방법 | |
| KR102400090B1 (ko) | 주름개선용 화장료 조성물 | |
| KR101033921B1 (ko) | 피부 염증 및 자극 완화 효과를 갖는 조성물 | |
| KR102675065B1 (ko) | 코나루스 세미데칸드러스 잎 추출물을 함유하는 아토피 피부염 개선용 화장료 조성물 | |
| Legiawati | Centella asiatica: alternative dry skin therapy in type 2 diabetes mellitus | |
| US20240091294A1 (en) | Extract of Top Growth of Holy Basil, and Cosmetic or Dermatological Compositions Containing Same | |
| KR20250054284A (ko) | 씨사이드에링고 배양물을 포함하는 피부 개선용 조성물 | |
| KR102475898B1 (ko) | 그라비올라 항균 추출물을 함유하는 화장료 조성물 및 그 제조방법 | |
| KR20190033334A (ko) | 민들레 뿌리 추출물, 카페인 및 토코페롤의 혼합물을 포함하는 피부 외용제 조성물 | |
| KR101310655B1 (ko) | 마름 추출물을 유효성분으로 포함하는 화장료 조성물 및 그 제조 방법 | |
| WO2017174988A1 (en) | Anti-inflammatory extract | |
| EP3042662A1 (fr) | Extraits de salade, compositions et utilisations | |
| KR100771523B1 (ko) | 테레인을 포함하는 피부 각질 형성세포 증식 억제제 | |
| KR101434446B1 (ko) | 참그물바탕말을 이용한 피부 외용제 조성물 | |
| KR20250046070A (ko) | 피부 상태 개선용 조성물 | |
| KR20250090792A (ko) | 팥꽃나무 소식물체 추출물을 포함하는 피부 개선 또는 상처 개선용 조성물 | |
| CN120712098A (zh) | 油茶树茶油浓缩物及其用途 | |
| Madoui et al. | Anti-inflammatory and healing effect of leaf-flower mixture extract of Cytisus triflorus L. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190814 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190821 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200907 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201208 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201223 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6829691 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |